Compare DGICB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | ADCT |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | Switzerland |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.4M | 484.4M |
| IPO Year | N/A | 2019 |
| Metric | DGICB | ADCT |
|---|---|---|
| Price | $17.69 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 2.0K | ★ 759.1K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $13.84 | $1.05 |
| 52 Week High | $20.30 | $4.98 |
| Indicator | DGICB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 43.30 |
| Support Level | $15.57 | $3.65 |
| Resistance Level | $17.80 | $3.87 |
| Average True Range (ATR) | 0.57 | 0.21 |
| MACD | 0.21 | -0.04 |
| Stochastic Oscillator | 66.75 | 29.73 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).